Superworth

EyePoint EPS EYPT

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$3.74
Latest quarter, Q2 FY26
−$1.09
Fiscal year 2025
−$3.16

EyePoint's earnings per share was −$3.74 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$1.09.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$3.16n/a
FY2024−$2.31n/a
FY2023−$1.83n/a
FY2022−$2.73n/a
FY2021−$2.02n/a
FY2020−$3.55n/a
FY2019−$5.60n/a
FY2018−$10.50n/a
FY2018−$13.30n/a
FY2017−$5.20n/a
FY2016−$6.90−463%
FY2015$1.90n/a
FY2014−$4.90n/a
FY2013−$5.10n/a
FY2012−$12.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$1.09n/a−$3.74
Q1 FY26−$0.99n/a−$3.50
Q4 FY25−$0.81n/a−$3.16
Q3 FY25−$0.85n/a−$2.99
Q2 FY25−$0.85n/a−$2.68
Q1 FY25−$0.65n/a−$2.41
Q4 FY24−$0.64n/a−$2.31
Q3 FY24−$0.54n/a−$2.00
Q2 FY24−$0.58n/a−$1.79
Q1 FY24−$0.55n/a−$1.82
Q4 FY23−$0.33n/a−$1.83
Q3 FY23−$0.33n/a−$2.66

Against its peers

Companies in Healthcare nearest EyePoint's size, closest first, today.

CompanyEPS, 12 monthsGrowth
EYPTEyePoint−$3.74
NEPHNephros$0.16+33% a year
ATNMActinium Pharmaceuticals$0.36
APTAlpha Pro Tech$0.41+24% a year
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
ICCCImmucell$0.08−58% a year
KEQUKewaunee Scientific$2.76−33% a year
PDEXPro DEX$4.11+52% a year
PLXProtalix BioTherapeutics$0.23+283% a year
NATRNatures Sunshine Products$1.01+36% a year
Peer median$0.38

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on EyePoint

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.